China Medical GatewayLoading your healthcare gateway…

Multiple Myeloma in China

Overview

Multiple myeloma is a cancer of plasma cells in the marrow that produces abnormal proteins damaging bones, kidneys and blood counts. Once uniformly fatal, it is now a chronic disease for most patients through novel-agent induction, transplant and maintenance.

Chinese hematology centers treat very large myeloma populations, with full access to proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies and CAR-T for relapsed disease.

Symptoms & Signs

Persistent bone pain, especially spine, ribs or hips, sometimes with fractures

Fatigue and weakness from anemia

Frequent infections from impaired antibody production

Excessive thirst and confusion from high calcium

Kidney impairment discovered on routine tests

Numbness or weakness from spinal cord compression by plasmacytoma — an emergency

Diagnosis

Serum and urine protein electrophoresis with immunofixation detecting monoclonal protein

Serum free light chain assay quantifying disease burden

Bone marrow biopsy with plasma cell percentage and cytogenetics

Whole-body low-dose CT or MRI skeletal survey mapping bone lesions

Kidney function and calcium assessment

FISH and NGS identifying risk-defining abnormalities such as del17p

Treatment Options

Induction therapy with triplet or quadruplet novel-agent combinations

Autologous stem cell transplantation consolidating first remission in fit patients

Maintenance therapy prolonging remission after transplant

Bisphosphonate-class or anti-RANKL therapy protecting bone

CAR-T cell therapy for multiply relapsed disease

Supportive care: hydration, infection prevention and renal management

Advanced Technologies & Novel Drug

Novel proteasome inhibitors and immunomodulatory agents as therapy backbones

BCMA-directed CAR-T approved for relapsed refractory myeloma

Minimal-residual-disease testing guiding treatment intensity

Anti-CD38 monoclonal antibodies in induction and relapse settings

Domestically developed novel agents available at Chinese hematology centers

Hospital & Specialist

Return to Home